Proton beam therapy in a patient with secondary glioblastoma (32 years after postoperative irradiation of medulloblastoma): case report and literature review.

IF 3.3 2区 医学 Q2 ONCOLOGY Radiation Oncology Pub Date : 2024-10-05 DOI:10.1186/s13014-024-02515-5
Bai Jiwei, Muyasha Abulimiti, Jin Yonglong, Wang Jie, Zhang Shuyan, Liu Chao, Wang Zishen, Wang Wei, Li Yinuo, Wang Weiwei, Yang Lu, Shosei Shimizu
{"title":"Proton beam therapy in a patient with secondary glioblastoma (32 years after postoperative irradiation of medulloblastoma): case report and literature review.","authors":"Bai Jiwei, Muyasha Abulimiti, Jin Yonglong, Wang Jie, Zhang Shuyan, Liu Chao, Wang Zishen, Wang Wei, Li Yinuo, Wang Weiwei, Yang Lu, Shosei Shimizu","doi":"10.1186/s13014-024-02515-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This report details the experience of a patient who developed a second primary glioblastoma (GB), offering insights into the treatment process and reviewing relevant literature.</p><p><strong>Case presentation: </strong>A male patient, who was diagnosed with medulloblastoma at age 9, received treatment with cobalt-60 craniospinal irradiation (CSI) (36 Gy/20 fractions) and a tumor bed boost (total of 56 Gy). After 32 years, at age 41, an MRI revealed a space-occupying mass in the left cerebellar hemisphere. Surgical resection was performed, and postoperative pathology confirmed a diagnosis of radiation-induced glioblastoma (RIGB). Given the history of irradiation and the current tolerability of brainstem doses, proton beam therapy (PBT) combined with Temozolomide (75 mg/m<sup>2</sup>) was chosen. The treatment plan included 60 Gy on the gross tumor bed and 54 Gy on the clinical target volume, delivered in 30 fractions. The patient underwent regular follow-up and achieved a complete response.</p><p><strong>Clinical discussion: </strong>For childhood cancer survivors, the development of a second primary tumor significantly impacts prognosis. RIGB is a rare form of secondary tumor with distinct molecular characteristics compared to primary GB and recurrent secondary GB. Molecular markers such as IDH and MGMT status can help differentiate between primary GB, recurrent secondary GB, and radiation-induced secondary GB in patients with a history of prior radiation therapy. Surgical resection remains a primary treatment option, while PBT is preferred for postoperative treatment due to its superior protection of normal tissues and the ability to deliver high-dose irradiation.</p><p><strong>Conclusion: </strong>RIGB is a rare second primary tumor that requires strategic molecular profiling and individualized management. Proton beam therapy provides effective high-dose irradiation in the postoperative phase and is the preferred treatment option for such cases.</p>","PeriodicalId":49639,"journal":{"name":"Radiation Oncology","volume":"19 1","pages":"136"},"PeriodicalIF":3.3000,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11453085/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiation Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13014-024-02515-5","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: This report details the experience of a patient who developed a second primary glioblastoma (GB), offering insights into the treatment process and reviewing relevant literature.

Case presentation: A male patient, who was diagnosed with medulloblastoma at age 9, received treatment with cobalt-60 craniospinal irradiation (CSI) (36 Gy/20 fractions) and a tumor bed boost (total of 56 Gy). After 32 years, at age 41, an MRI revealed a space-occupying mass in the left cerebellar hemisphere. Surgical resection was performed, and postoperative pathology confirmed a diagnosis of radiation-induced glioblastoma (RIGB). Given the history of irradiation and the current tolerability of brainstem doses, proton beam therapy (PBT) combined with Temozolomide (75 mg/m2) was chosen. The treatment plan included 60 Gy on the gross tumor bed and 54 Gy on the clinical target volume, delivered in 30 fractions. The patient underwent regular follow-up and achieved a complete response.

Clinical discussion: For childhood cancer survivors, the development of a second primary tumor significantly impacts prognosis. RIGB is a rare form of secondary tumor with distinct molecular characteristics compared to primary GB and recurrent secondary GB. Molecular markers such as IDH and MGMT status can help differentiate between primary GB, recurrent secondary GB, and radiation-induced secondary GB in patients with a history of prior radiation therapy. Surgical resection remains a primary treatment option, while PBT is preferred for postoperative treatment due to its superior protection of normal tissues and the ability to deliver high-dose irradiation.

Conclusion: RIGB is a rare second primary tumor that requires strategic molecular profiling and individualized management. Proton beam therapy provides effective high-dose irradiation in the postoperative phase and is the preferred treatment option for such cases.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
质子束治疗继发性胶质母细胞瘤患者(髓母细胞瘤术后照射后32年):病例报告和文献综述。
摘要本报告详细介绍了一名罹患第二原发性胶质母细胞瘤(GB)患者的经历,对治疗过程提出了见解,并回顾了相关文献:一名男性患者在 9 岁时被诊断为髓母细胞瘤,接受了钴-60 颅椎体照射(CSI)(36 Gy/20 次)和肿瘤床增量(共 56 Gy)治疗。32 年后,41 岁时,核磁共振成像显示左侧小脑半球有一个占位性肿块。患者接受了手术切除,术后病理确诊为辐射诱导的胶质母细胞瘤(RIGB)。考虑到患者的照射史和目前脑干剂量的耐受性,患者选择了质子束疗法(PBT)联合替莫唑胺(75 mg/m2)。治疗计划包括对肿瘤床进行 60 Gy 照射,对临床靶区进行 54 Gy 照射,分 30 次进行。患者接受了定期随访,并获得了完全反应:临床讨论:对于儿童癌症幸存者来说,第二个原发性肿瘤的发生会严重影响预后。RIGB 是一种罕见的继发性肿瘤,与原发性 GB 和复发性继发性 GB 相比,具有明显的分子特征。IDH 和 MGMT 状态等分子标记物有助于区分原发性 GB、复发性继发性 GB 和曾接受过放射治疗的患者中由辐射诱发的继发性 GB。手术切除仍是主要的治疗方案,而PBT因其对正常组织的良好保护和高剂量照射的能力而成为术后治疗的首选:RIGB是一种罕见的第二原发性肿瘤,需要进行战略性分子分析和个体化治疗。质子束疗法可在术后阶段提供有效的高剂量照射,是此类病例的首选治疗方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Radiation Oncology
Radiation Oncology ONCOLOGY-RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
CiteScore
6.50
自引率
2.80%
发文量
181
审稿时长
3-6 weeks
期刊介绍: Radiation Oncology encompasses all aspects of research that impacts on the treatment of cancer using radiation. It publishes findings in molecular and cellular radiation biology, radiation physics, radiation technology, and clinical oncology.
期刊最新文献
The impact of radiation-related lymphocyte recovery on the prognosis of locally advanced esophageal squamous cell carcinoma patients: a retrospective analysis. Correction: Artificial intelligence contouring in radiotherapy for organs-at-risk and lymph node areas. Deep learning-based synthetic CT for dosimetric monitoring of combined conventional radiotherapy and lattice boost in large lung tumors. Correction: The significance of risk stratification through nomogram-based assessment in determining postmastectomy radiotherapy for patients diagnosed with pT1 - 2N1M0 breast cancer. Sequential or simultaneous-integrated boost in early-stage breast cancer patients: trade-offs between skin toxicity and risk of compromised coverage.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1